Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.

Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.

The present invention relates to the use of a farnesoid X receptor (FXR) agonist for the treatment of hepatitis D infection.

The present invention relates to the use of a farnesoid X receptor (FXR) agonist for the treatment of hepatitis D infection.

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

A method of treating and/or preventing disease wherein retinal pigment epithelium, including administering compound of formula (I)

##STR00001##

or pharmaceutically acceptable salt, racemic mixture, corresponding enantiomer or, if applicable, corresponding diastereomer, wherein: X is either NH or O, R.sub.11, R.sub.12 and R.sub.13 are independently selected from consisting hydrogen group, fluoro, chloro, trifluoromethyl, methyl and difluoromethoxy, A is selected from consisting residue group of formula (II)-(VII) or (VIII)

##STR00002##

“*” denotes point of attachment to molecule remainder, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.2.sup.I, R.sub.3.sup.I, R.sub.4.sup.I, R.sub.5.sup.I, R.sub.2.sup.II, R.sub.3.sup.II, R.sub.4.sup.II, R.sub.5.sup.II, R.sub.2.sup.III, R.sub.3.sup.III, R.sub.4.sup.III, R.sub.5.sup.III, R.sub.2.sup.IV, R.sub.3.sup.IV, R.sub.4.sup.IV, R.sub.5.sup.IV, R.sub.2.sup.V, R.sub.3.sup.V, R.sub.4.sup.V, R.sub.5.sup.V, R.sub.2.sup.VI, R.sub.3.sup.VI, R.sub.4.sup.VI and R.sub.5.sup.VI are independently selected from hydrogen consisting group, linear or branched alkyl having 1-3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl, 2,2,2-trifluoroethyl and difluoromethoxy and R.sub.6 is selected from hydrogen consisting group, linear or branched alkyl having 1-3 carbon atoms, trifluoromethyl, and 2,2,2-trifluoroethyl.

A method of treating and/or preventing disease wherein retinal pigment epithelium, including administering compound of formula (I)

##STR00001##

or pharmaceutically acceptable salt, racemic mixture, corresponding enantiomer or, if applicable, corresponding diastereomer, wherein: X is either NH or O, R.sub.11, R.sub.12 and R.sub.13 are independently selected from consisting hydrogen group, fluoro, chloro, trifluoromethyl, methyl and difluoromethoxy, A is selected from consisting residue group of formula (II)-(VII) or (VIII)

##STR00002##

“*” denotes point of attachment to molecule remainder, and R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.2.sup.I, R.sub.3.sup.I, R.sub.4.sup.I, R.sub.5.sup.I, R.sub.2.sup.II, R.sub.3.sup.II, R.sub.4.sup.II, R.sub.5.sup.II, R.sub.2.sup.III, R.sub.3.sup.III, R.sub.4.sup.III, R.sub.5.sup.III, R.sub.2.sup.IV, R.sub.3.sup.IV, R.sub.4.sup.IV, R.sub.5.sup.IV, R.sub.2.sup.V, R.sub.3.sup.V, R.sub.4.sup.V, R.sub.5.sup.V, R.sub.2.sup.VI, R.sub.3.sup.VI, R.sub.4.sup.VI and R.sub.5.sup.VI are independently selected from hydrogen consisting group, linear or branched alkyl having 1-3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl, 2,2,2-trifluoroethyl and difluoromethoxy and R.sub.6 is selected from hydrogen consisting group, linear or branched alkyl having 1-3 carbon atoms, trifluoromethyl, and 2,2,2-trifluoroethyl.

The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R.sup.1, R.sup.2a, and R.sup.2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.

##STR00001##

The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R.sup.1, R.sup.2a, and R.sup.2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.

##STR00001##